Fifteen drug manufacturers supply more than 90 % of antiretroviral drugs ( ARVs ) , crucial treatments for HIV and AIDS , to low and middle - income countries , according to the aids Nations programme on HIV / AIDS . Of these firms , just four supply a staggering 83 % of the drugs , which prevents the growth of the AIDS virus . Therefore , these disruptions could have serious implications for millions of people . Last year , an Indian factory owned by major supplier companies was found to have deficiencies that could lead to the suspension of production of ARVs .
Fifteen drug manufacturers supply more than 95% of antiretroviral drugs (ARVs), crucial treatments for HIV and AIDS, to low and middle-income countries, according to the United Nations programme on HIV/AIDS. Of these firms, just four supply a staggering 83% of the drugs, which slow the growth of the AIDS virus. Therefore, supply disruptions could have serious implications for millions of people. Last year, an Indian factory owned by major supplier Mylan was found to have deficiencies that could lead to the suspension of production of ARVs.